Nanochemistry Modulates Intracellular Decomposition Routes of S‐Nitrosothiol Modified Silica‐Based Nanoparticles
Source abstract
Abstract
Abstract Cellular delivery of nitric oxide (NO) using NO donor moieties such as S‐nitrosothiol (SNO) is of great interest for various applications. However, understandings of the intracellular decomposition routes of SNO toward either NO or ammonia (NH3) production are surprisingly scarce. Herein, the first report of SNO modified mesoporous organosilica nanoparticles with tetrasulfide bonds for enhanced intracellular NO delivery, ≈10 times higher than a commercial NO donor, is presented. The tetrasulfide chemistry modulates the SNO decomposition by shifting from NH3 to NO production in glutathione rich cancer cells. This study provides a new strategy to control the NO level in biological systems.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nitric Oxide and Endothelin Effects · Nanoplatforms for cancer theranostics · Sulfur Compounds in Biology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Australian Institute for Bioengineering and Nanotechnology The University of Queensland Brisbane QLD 4072 Australia
School of Chemistry and Molecular Engineering East China Normal University Shanghai 200241 China
Funding
Australian Research Council · Queensland Government · Australian National Fabrication Facility · University of Queensland
References (41)
Show source-provided references
1. 10.1021/acs.jmedchem.6b0167210.1021/acs.jmedchem.6b01672 ↗
2. 10.1038/sj.cr.729013310.1038/sj.cr.7290133 ↗
3. 10.1038/nrc191010.1038/nrc1910 ↗
4. 10.1002/adhm.20190025610.1002/adhm.201900256 ↗
5. 10.1039/C8TB00299A10.1039/C8TB00299A ↗
6. 10.1021/acs.molpharmaceut.9b0087210.1021/acs.molpharmaceut.9b00872 ↗
7. 10.1021/cr000040l10.1021/cr000040l ↗
8. 10.1006/niox.2000.031510.1006/niox.2000.0315 ↗
9. 10.1002/anie.20180059410.1002/anie.201800594 ↗
10. 10.1073/pnas.93.25.1442810.1073/pnas.93.25.14428 ↗
11. 10.1042/bj2002164910.1042/bj20021649 ↗
12. 10.1039/c2cs15272j10.1039/c2cs15272j ↗
13. 10.1039/C2CC37181B10.1039/C2CC37181B ↗
14. 10.1021/acs.molpharmaceut.7b0100110.1021/acs.molpharmaceut.7b01001 ↗
15. 10.1016/j.actbio.2019.12.01610.1016/j.actbio.2019.12.016 ↗
16. 10.1016/j.jcis.2015.08.01110.1016/j.jcis.2015.08.011 ↗
17. 10.1021/acsami.8b1923610.1021/acsami.8b19236 ↗
18. 10.1016/j.polymer.2014.12.02010.1016/j.polymer.2014.12.020 ↗
19. 10.1039/D0TB00734J10.1039/D0TB00734J ↗
20. 10.1021/acs.nanolett.8b0423610.1021/acs.nanolett.8b04236 ↗
21. 10.1039/c2cs15273h10.1039/c2cs15273h ↗
22. 10.1002/anie.20150453610.1002/anie.201504536 ↗
23. 10.1016/j.mam.2008.08.00610.1016/j.mam.2008.08.006 ↗
24. Russo A. · Cancer Res. · 1986 · 46 · 2845
25. 10.1016/j.phrs.2020.10474210.1016/j.phrs.2020.104742 ↗
26. 10.1021/acs.chemmater.6b0389610.1021/acs.chemmater.6b03896 ↗
27. 10.1016/j.biomaterials.2018.05.02510.1016/j.biomaterials.2018.05.025 ↗
28. 10.1039/C8TB00544C10.1039/C8TB00544C ↗
29. 10.1039/C2CP42811C10.1039/C2CP42811C ↗
30. 10.1021/la302357h10.1021/la302357h ↗
31. 10.1039/c3nr33280b10.1039/c3nr33280b ↗
32. 10.1021/cm102510q10.1021/cm102510q ↗
33. 10.1016/j.freeradbiomed.2007.04.02610.1016/j.freeradbiomed.2007.04.026 ↗
34. 10.3390/cancers301128510.3390/cancers3011285 ↗
35. 10.1039/C5CC10606K10.1039/C5CC10606K ↗
36. 10.1016/j.jconrel.2016.12.02610.1016/j.jconrel.2016.12.026 ↗
37. 10.1002/smll.20090000510.1002/smll.200900005 ↗
38. 10.1007/s40005-017-0356-210.1007/s40005-017-0356-2 ↗
39. 10.1002/adma.20180395310.1002/adma.201803953 ↗
40. 10.2174/13816121079023214910.2174/138161210790232149 ↗
41. Lv H. · Oxid. Med. Cell. Longevity · 2019 · 2019 · 3150145